IGF1R and esophageal squamous cell carcinoma: Gefitinib, lapatinib, and linsitinib showed similar inhibitory activity on the proliferation of four ESCC cells, although the four ESCC cells had variable levels of EGFR, HER2, and IGF-1R, as revealed by MTT assays.